<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00486837</url>
  </required_header>
  <id_info>
    <org_study_id>100452</org_study_id>
    <nct_id>NCT00486837</nct_id>
  </id_info>
  <brief_title>Deposition of Inhaled Prolastin in Cystic Fibrosis Patients</brief_title>
  <acronym>CF2</acronym>
  <official_title>Multicenter, Randomized, Parallel Group Study to Investigate the Optimal Deposition Site for Inhaled Prolastin® in Patients With Cystic Fibrosis (CF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grifols Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grifols Therapeutics LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this trial is to determine the optimal region of the lung for depositing
      Prolastin (alpha-1 antitrypsin; AAT) by inhalation in order to treat cystic fibrosis (CF).
      The AKITA® nebulizer has settings which can be varied to target the inhaled drug to either
      the deep lung or to the upper airways in a one to one randomization. The study will measure
      how much of the activity of the enzyme elastase is inhibited by AAT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The optimum deposition site (bronchial or peripheral) in CF patients for AAT will be
      investigated by measuring several parameters in induced sputum. The study will start with a 2
      week run-in period in which the planned 60 patients inhale isotonic saline once daily. This
      period is followed by a 4 week treatment period where 30 patients inhale AAT for peripheral
      deposition and 30 patients inhale AAT for bronchial deposition. Six patients in each group
      will be asked to collect spontaneous sputum at home.

      Twenty-five milligrams of AAT will be deposited at one of the two target sites using the
      AKITA® device. The inhalation should take place in the evening between 18.00 and 23.00 h.

      Patients will inhale saline once daily for 2 weeks (run-in period) followed by 4 weeks of
      once daily inhalation of AAT. Induced sputum will be collected at visits to the clinic at the
      start of the run-in, at the start of AAT treatment, and at 2 and 4 weeks after the start of
      AAT treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">June 2004</completion_date>
  <primary_completion_date type="Actual">June 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Free Elastase in Induced Sputum From Baseline to Week 4</measure>
    <time_frame>Baseline vs Week 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Alpha-1-anti-trypsin (A1AT) Activity in Induced Sputum From Baseline at Week 4</measure>
    <time_frame>Baseline vs Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Immunoglobulin G (IgG) Fragments in Induced Sputum From Baseline at Week 4</measure>
    <time_frame>Baseline vs Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Bacterial Load in Induced Sputum From Baseline to Week 4</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pseudomonas Load in Induced Sputum From Baseline at Week 4</measure>
    <time_frame>Baseline vs Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Neutrophil Number in Induced Sputum From Baseline at Week 4</measure>
    <time_frame>Baseline vs Week 4</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bronchial Deposition Intervention: Alpha1-Proteinase Inhibitor (Human) Dosage: 25 mg in lungs, one inhalation per day over 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peripheral Deposition Intervention: Alpha1-Proteinase Inhibitor (Human) Dosage: 25 mg in lungs, one inhalation per day over 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alpha1-Proteinase Inhibitor (Human)</intervention_name>
    <description>25 mg of Alpha1-Proteinase Inhibitor (Human) in the lungs, one inhalation per day over 4 weeks.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Prolastin®</other_name>
    <other_name>Alpha-1 antitrypsin (AAT)</other_name>
    <other_name>BAY x 5747</other_name>
    <other_name>BAY 10-5233</other_name>
    <other_name>TAL-05-00007</other_name>
    <other_name>A1AT</other_name>
    <other_name>NDC 13533-601-30</other_name>
    <other_name>NDC 13533-601-35</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with diagnosis of CF

          -  Age &gt;= 8 years

          -  Forced expiratory volume at one second (FEV1) &gt; 25 % of predicted value

          -  Free elastase activity checked at visit 1 must be positive (free elastolytic activity
             in the sample, 2 standard deviations above of the negative blank samples in the
             assay.) .

          -  Patient must be positive at least 3 times for pseudomonas in the last 2 years

          -  Patient must be positive for pseudomonas at Visit 1

          -  Patient must be able to perform reliable spirometry

          -  Patient must be on stable concomitant therapy at least 2 weeks prior to visit 1 and
             during the study

          -  Written informed consent of the patient or legal representative(s)

        Exclusion Criteria:

          -  FEV1 &lt; 25% of predicted value post-bronchodilator

          -  History of lung transplant

          -  Any lung surgery within the past 2 years

          -  On any thoracic surgery waiting list

          -  Severe concomitant disease (serious malignant disease, congestive heart failure New
             York Heart Association (NYHA) III/IV, cor pulmonale with the need of oxygen therapy)

          -  Severe liver cirrhosis with ascites, hypersplenism or grade III/IV esophageal varices.

          -  Known selective immunoglobulin A (IgA) deficiency with known antibody against IgA
             (anti-IgA antibody)

          -  Active pulmonary exacerbation within the 4 weeks prior to screening

          -  Current Smoking

          -  Pregnancy or lactation

          -  Women of child-bearing age without adequate contraception

          -  Any medical condition which the investigator feels will prohibit the patient from
             completing the trial

          -  Participation in another clinical trial within 30 days prior to inclusion at visit 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Griese, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kinderklinik und Kinderpoliklinik im Haunerschen Kinderspital</affiliation>
  </overall_official>
  <link>
    <url>http://www.fda.gov/opacom/enforce.html</url>
    <description>FDA Enforcement Report Index (Class I, Class II Recall, Market Alerts and Medical Product Safety Alerts)</description>
  </link>
  <results_reference>
    <citation>Griese M, Latzin P, Kappler M, Weckerle K, Heinzlmaier T, Bernhardt T, Hartl D. alpha1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. Eur Respir J. 2007 Feb;29(2):240-50. Epub 2006 Oct 18.</citation>
    <PMID>17050563</PMID>
  </results_reference>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2007</study_first_submitted>
  <study_first_submitted_qc>June 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2007</study_first_posted>
  <results_first_submitted>September 24, 2009</results_first_submitted>
  <results_first_submitted_qc>August 5, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 21, 2014</results_first_posted>
  <last_update_submitted>August 5, 2014</last_update_submitted>
  <last_update_submitted_qc>August 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alpha 1-Antitrypsin</mesh_term>
    <mesh_term>Protease Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was performed in 8 study centers in Germany.</recruitment_details>
      <pre_assignment_details>Subjects inhaled saline once daily for 2 weeks during the Run-in Period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Peripheral Deposition</title>
          <description>Peripheral Deposition is achieved with a breathing maneuver consisting of slow and deep breaths</description>
        </group>
        <group group_id="P2">
          <title>Bronchial Deposition</title>
          <description>Bronchial Deposition consists of inhalation of smaller volumes per breath at higher flow rates</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No sputum, devise issues, exacerbation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Peripheral Deposition</title>
          <description>Peripheral Deposition is achieved with a breathing maneuver consisting of slow and deep breaths</description>
        </group>
        <group group_id="B2">
          <title>Bronchial Deposition</title>
          <description>Bronchial Deposition consists of inhalation of smaller volumes per breath at higher flow rates</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="37"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="72"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.78" spread="7.54"/>
                    <measurement group_id="B2" value="27.42" spread="9.78"/>
                    <measurement group_id="B3" value="25.46" spread="8.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Free Elastase during the Run-In Phase</title>
          <units>µg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.6" spread="35.9"/>
                    <measurement group_id="B2" value="35.9" spread="38.8"/>
                    <measurement group_id="B3" value="36.2" spread="36.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.7" spread="31.7"/>
                    <measurement group_id="B2" value="25.0" spread="20.1"/>
                    <measurement group_id="B3" value="29.1" spread="27.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-4.0" spread="21.3"/>
                    <measurement group_id="B2" value="-10.9" spread="36.9"/>
                    <measurement group_id="B3" value="-7.25" spread="29.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Free Elastase in Induced Sputum From Baseline to Week 4</title>
        <time_frame>Baseline vs Week 4</time_frame>
        <population>Modified Intent-to-Treat Population (mITT) was all randomized subjects who received any amount of study medication and had at least one evaluation of the primary efficacy variable (free elastase in induced sputum) post baseline and at baseline (Visit 2).</population>
        <group_list>
          <group group_id="O1">
            <title>Peripheral Deposition</title>
            <description>Peripheral Deposition is achieved with a breathing maneuver consisting of slow and deep breaths</description>
          </group>
          <group group_id="O2">
            <title>Bronchial Deposition</title>
            <description>Bronchial Deposition consists of inhalation of smaller volumes per breath at higher flow rates</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Free Elastase in Induced Sputum From Baseline to Week 4</title>
          <population>Modified Intent-to-Treat Population (mITT) was all randomized subjects who received any amount of study medication and had at least one evaluation of the primary efficacy variable (free elastase in induced sputum) post baseline and at baseline (Visit 2).</population>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.42" spread="29.96"/>
                    <measurement group_id="O2" value="6.11" spread="31.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.197</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Alpha-1-anti-trypsin (A1AT) Activity in Induced Sputum From Baseline at Week 4</title>
        <time_frame>Baseline vs Week 4</time_frame>
        <population>For Group 1, only 24 out of 28 subjects had applicable data to analyze. For Group 2, only 27 out of 28 subjects had applicable data to analyze.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Bronchial Deposition
Alpha1-Proteinase Inhibitor (Human): 25 mg of Alpha1-Proteinase Inhibitor (Human) in the lungs, one inhalation per day over 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Peripheral Deposition
Alpha1-Proteinase Inhibitor (Human): 25 mg of Alpha1-Proteinase Inhibitor (Human) in the lungs, one inhalation per day over 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Alpha-1-anti-trypsin (A1AT) Activity in Induced Sputum From Baseline at Week 4</title>
          <population>For Group 1, only 24 out of 28 subjects had applicable data to analyze. For Group 2, only 27 out of 28 subjects had applicable data to analyze.</population>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16741" spread="33583"/>
                    <measurement group_id="O2" value="6469" spread="18999"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Immunoglobulin G (IgG) Fragments in Induced Sputum From Baseline at Week 4</title>
        <time_frame>Baseline vs Week 4</time_frame>
        <population>For Group 1, only 24 out of 28 subjects had applicable data to analyze. For Group 2, only 26 out of 28 subjects had applicable data to analyze.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Bronchial Deposition
Alpha1-Proteinase Inhibitor (Human): 25 mg of Alpha1-Proteinase Inhibitor (Human) in the lungs, one inhalation per day over 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Peripheral Deposition
Alpha1-Proteinase Inhibitor (Human): 25 mg of Alpha1-Proteinase Inhibitor (Human) in the lungs, one inhalation per day over 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Immunoglobulin G (IgG) Fragments in Induced Sputum From Baseline at Week 4</title>
          <population>For Group 1, only 24 out of 28 subjects had applicable data to analyze. For Group 2, only 26 out of 28 subjects had applicable data to analyze.</population>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.005" spread="1.10"/>
                    <measurement group_id="O2" value="-0.48" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Bacterial Load in Induced Sputum From Baseline to Week 4</title>
        <time_frame>Week 4</time_frame>
        <population>For Group 1, only 24 out of 28 subjects had applicable data to analyze. For Group 2, all 28 subjects had applicable data to analyze.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Bronchial Deposition
Alpha1-Proteinase Inhibitor (Human): 25 mg of Alpha1-Proteinase Inhibitor (Human) in the lungs, one inhalation per day over 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Peripheral Deposition
Alpha1-Proteinase Inhibitor (Human): 25 mg of Alpha1-Proteinase Inhibitor (Human) in the lungs, one inhalation per day over 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Bacterial Load in Induced Sputum From Baseline to Week 4</title>
          <population>For Group 1, only 24 out of 28 subjects had applicable data to analyze. For Group 2, all 28 subjects had applicable data to analyze.</population>
          <units>CFU/g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22673275.8" spread="253455845.23"/>
                    <measurement group_id="O2" value="5021353.2" spread="130686274.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pseudomonas Load in Induced Sputum From Baseline at Week 4</title>
        <time_frame>Baseline vs Week 4</time_frame>
        <population>For Group 1, only 24 out of 28 subjects had applicable data to analyze. For Group 2, all 28 subjects had applicable data to analyze.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Bronchial Deposition
Alpha1-Proteinase Inhibitor (Human): 25 mg of Alpha1-Proteinase Inhibitor (Human) in the lungs, one inhalation per day over 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Peripheral Deposition
Alpha1-Proteinase Inhibitor (Human): 25 mg of Alpha1-Proteinase Inhibitor (Human) in the lungs, one inhalation per day over 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pseudomonas Load in Induced Sputum From Baseline at Week 4</title>
          <population>For Group 1, only 24 out of 28 subjects had applicable data to analyze. For Group 2, all 28 subjects had applicable data to analyze.</population>
          <units>CFU/g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.1" spread="808.2"/>
                    <measurement group_id="O2" value="-22.3" spread="772.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Neutrophil Number in Induced Sputum From Baseline at Week 4</title>
        <time_frame>Baseline vs Week 4</time_frame>
        <population>For Group 1, only 21 out of 28 subjects had applicable data to analyze. For Group 2, only 22 out of 28 subjects had applicable data to analyze.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Bronchial Deposition
Alpha1-Proteinase Inhibitor (Human): 25 mg of Alpha1-Proteinase Inhibitor (Human) in the lungs, one inhalation per day over 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Peripheral Deposition
Alpha1-Proteinase Inhibitor (Human): 25 mg of Alpha1-Proteinase Inhibitor (Human) in the lungs, one inhalation per day over 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Neutrophil Number in Induced Sputum From Baseline at Week 4</title>
          <population>For Group 1, only 21 out of 28 subjects had applicable data to analyze. For Group 2, only 22 out of 28 subjects had applicable data to analyze.</population>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.8" spread="30.3"/>
                    <measurement group_id="O2" value="-8.2" spread="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Peripheral Deposition</title>
          <description>Peripheral Deposition is achieved with a breathing maneuver consisting of slow and deep breaths</description>
        </group>
        <group group_id="E2">
          <title>Bronchial Deposition</title>
          <description>Bronchial Deposition consists of inhalation of smaller volumes per breath at higher flow rates</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis Allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator must send a draft manuscript of the publication or abstract to the sponsor thirty days in advance of submission in order to obtain approval prior to submission of the final version for publication. This will be reviewed promptly and approval will not be withheld unreasonably. In case of a difference of opinion between the sponsor and the Investigator(s), the contents of the publication will be discussed in order to find a solution which satisfies both parties.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Henry Li</name_or_title>
      <organization>Grifols Therapeutics</organization>
      <phone>1-800-520-2807</phone>
      <email>henry.li@grifols.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

